This Article Full Text Full Text (PDF) CME: Take the course for this article: Chemoembolization in the Management of Liver Tumors eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Stuart, K. Search for Related Content PubMed PubMed Citation Articles by Stuart, K.

Chemoembolization in the Management of Liver Tumors

Gastrointestinal and Hepatobiliary Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA

Correspondence: Keith Stuart, M.D., Gastrointestinal and Hepatobiliary Oncology Program, Beth Israel Deaconess Medical Center, Boston, Massachusetts 02215, USA. Telephone: 617-667-9235; Fax: 617-975-5665; e-mail: kstuart{at}bidmc.harvard.edu

The dual vascular supply of the liver affords a unique opportunity to explore intraarterial therapies for hepatic malignancies. Chemoembolization is a well-established technique combining intra-arterial chemotherapy with delivery of embolic agents in order to achieve an antitumor effect due to a high local concentration and prolonged dwell time of the drug, along with select ischemia. Many tumors, such as hepatocellular carcinoma, colorectal cancer, and neuroendocrine tumors, cause symptoms and death by local growth and destruction of the liver. While there are other methods capable of controlling small or isolated hepatic neoplasms, none are suitable for the majority of these patients. Chemoembolization can produce significant results in terms of tumor shrinkage in many of these patients, and there are studies to suggest a survival advantage in hepatocellular carcinoma. Toxicity, however, may be substantial, and patient selection is crucial in order to achieve the optimal benefit of this powerful technique for individual populations.

Key Words. Hepatocellular carcinoma • Chemoembolization • Liver metastases

This article has been cited by other articles:

				K. V. Sharma, J. E. Gould, J. W. Harbour, G. P. Linette, T. K. Pilgram, P. N. Dayani, and D. B. Brown Hepatic Arterial Chemoembolization for Management of Metastatic Melanoma Am. J. Roentgenol., January 1, 2008; 190(1): 99 - 104. [Abstract] [Full Text] [PDF]

				M. Suzuki, Y. Sakurai, S. Hagiwara, S. Masunaga, Y. Kinashi, K. Nagata, A. Maruhashi, M. Kudo, and K. Ono First Attempt of Boron Neutron Capture Therapy (BNCT) for Hepatocellular Carcinoma Jpn. J. Clin. Oncol., June 19, 2007; (2007) hym039v1. [Abstract] [Full Text] [PDF]

				C.-S. Lin, Y.-M. Jen, S.-Y. Chiu, J.-M. Hwang, H.-L. Chao, H.-Y. Lin, and W.-Y. Shum Treatment of Portal Vein Tumor Thrombosis of Hepatoma Patients with Either Stereotactic Radiotherapy or Three-Dimensional Conformal Radiotherapy Jpn. J. Clin. Oncol., April 1, 2006; 36(4): 212 - 217. [Abstract] [Full Text] [PDF]